SLC18A2 and Chorea: Two FDA-approved drugs for the symptomatic treatment of HD-mediated chorea, tetrabenazine and deutetrabenazine, target the dopaminergic pathway through inhibition of the vesicular monoamine transporter (VMAT2 inhibitor), resulting in decreased bioavailability of dopamine in synapses and reduced dopamine signalling.